Sentences with phrase «b cell survival»

GSK3 function is essential for B cell survival in germinal centers.

Not exact matches

The generation of the germinal centers requires B cells to undergo a complex transcriptional program to allow them to divide rapidly, modify their antibody genes, and pass through a selection procedure that induces either their survival or their death.

Exon - Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B - Cell / Follicular Grade 3 Lymphoma Patients Treated with Dose - Dense Chemoimmuno - therapy and CNS Prophylaxis.

Use of exon - based transcriptome profiling to identify novel signaling pathways and survival - associated genes in diffuse large B - cell lymphoma.

Pagès F, Berger A, Camus M, Sanchez - Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugenc P - H, Trajanoski Z, Fridman W - H, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer.

c - Rel is essential for B lymphocyte survival and cell cycle progression.

(PMID: 9312132) Download PDF [ii] Wong BR, Josien R, Lee SY, Sauter B, Li H - L, Steinman RM, Choi Y. TRANCE, a new TNF family member predominantly expressed in T cells, is a dendritic cell specific survival factor.

Hsiou - Chi Liou and colleagues find that c - Rel, a lymphoid - specific member of the NF - kappaB / Rel family of transcriptional factors, is essential for B lymphocyte survival and cell cycle progression, [i] and that it is important for inducible cytokine and cytokine receptor expression and a key regulator of early activation and proliferation in T cells.

CD9 may contribute to the survival of human germinal center B cells by facilitating the interaction with follicular dendritic cells.

Title: Hematopoietic Stem Cell Function and Survival Depend on c - Myc and N - Myc Activity Authors: Laurenti E, Varnum - Finney B, Wilson A, Ferrero I, Blanco - Bose WE, Ehninger A, Knoepfler PS, Cheng PF, MacDonald HR, Eisenman RN, Bernstein ID, Trumpp A Date: 2008 Publication Details: Cell Stem Cell, Volume 3, Issue 6, 611 - 624, 4 December 2008

(B) Survival of gp33 and NP396 CD8 T cell — immunized mice with LCMV infection following 30 d rest period compared with control mice.

(B) Survival of mice after intracardiac injection of 1833 (1 × 105) breast cancer cells and treatment with either dimethyl sulfoxide (DMSO) control or the allosteric ABL inhibitor GNF5.

(B) Survival of mice after intracardiac injection of 1833 (1 × 105) breast cancer cells transduced with control shRNA (Scr) or shRNAs against ABL1 and ABL2 (shAA); n = 10 mice per group.

Long - term Tumor - free Survival With Untreated Primary Diffuse Large B - Cell Lymphoma of the Tonsil: A Report of 9 Cases.

High - Dose Chemotherapy Plus Transplant Not Recommended for DLBCL: The results of an Italian study report that treatment of high - risk diffuse large B - cell lymphoma (DLBCL) with abbreviated course of rituximab dose - dense chemotherapy plus high - dose cytarabine, mitoxantrone, and dexamethasone (R - MAD) plus carmustine, etoposide, cytarabine, and melphalan (BEAM) plus autologous stem cell transplantation compared with a full course of rituximab dose - dense chemotherapy did not improve overall survival.

Current practice is therefore based on findings from early - phase and retrospective primary CNS lymphoma studies, and extrapolations of survival data among patients with systemic B - cell lymphoma, Dr. Doorduijn said.

Areas of focus include: understanding how tumour - reactive T cells and B cells promote patient survival in cancer; defining the effects of standard treatments on tumor immunity; and using genomic approaches to identify novel tumour mutations that can serve as target antigens for immunotherapy.

B - cell chronic lymphocytic leukemia (B - CLL) is a common cancer in dogs, but little is known about the disease, including its clinical progression and survival expectations for patients.

Unfortunately, most dogs treated with chemotherapy for b - cell lymphoma see remission of only one year (median is 9 months), however, the two year survival rate is 20 %.

Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, et al. (2011) CD40 - Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma.

The classification of LSA as B - cell or T - cell sub-types is important because this distinction is valuable for the specialist to predict duration of remission and overall survival.

With standard of care treatment, B cell lymphomas with treatment may have an average survival of 9 - 12 months and those with T cell lymphomas may have an average survival of 6 - 9 months.

Rituximab Improves Overall Survival in Patients Treated with CODOX - M / IVAC for Burkitt Lymphoma (BL) and B - Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B - Cell Lymphoma and BL (BCL - U): A Single Center Experience and Review of the Literature